RESUMEN
This report describes a case of facial hyperpigmentation in a patient with Crohn's disease receiving adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor. The onset of hyperpigmentation coincided with adalimumab administration, and its discontinuation resulted in significant improvement. Histopathological findings suggest a postinflammatory process at the dermo-epidermal junction. However, the precise mechanism remains unclear.
Asunto(s)
Adalimumab , Enfermedad de Crohn , Hiperpigmentación , Humanos , Adalimumab/efectos adversos , Hiperpigmentación/inducido químicamente , Hiperpigmentación/patología , Enfermedad de Crohn/tratamiento farmacológico , Antiinflamatorios/efectos adversos , Antiinflamatorios/uso terapéutico , Femenino , Adulto , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Cara/patología , MasculinoAsunto(s)
Hipopigmentación , Humanos , Hipopigmentación/patología , Pigmentación de la Piel , Masculino , FemeninoRESUMEN
Breast cancer is the first cancer associated with cutaneous metastasis (CM). The clinical presentation of these metastases is comprehensive. We report an original case of carcinoma en cuirasse associated with zosteriform metastasis that indicates the development of contralateral breast cancer.
Asunto(s)
Exantema , Pitiriasis Liquenoide , Niño , Exantema/diagnóstico , Exantema/etiología , Humanos , NecrosisRESUMEN
There is a clinical overlap between hypervascularized sarcomas and arteriovenous malformations (AVM). MRI imaging should be interpreted with caution keeping in mind that some cancers could mimic AVM. A biopsy is mandatory in doubtful cases.
